株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脊髄小脳変性症(SCA)- 疫学予測 2028年

Spinocerebellar Ataxia (SCA) - Epidemiology Forecast to 2028

発行 DelveInsight Business Research LLP 商品コード 909906
出版日 ページ情報 英文 80 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
脊髄小脳変性症(SCA)- 疫学予測 2028年 Spinocerebellar Ataxia (SCA) - Epidemiology Forecast to 2028
出版日: 2019年09月01日 ページ情報: 英文 80 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の脊髄小脳変性症(SCA)の2017年の有病数は4万2,043人と推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の脊髄小脳変性症(SCA)市場を調査し、市場および疾患の概要、国別の疫学的予測、病型別の有病数および診断数の推移、アンメットニーズなどについてまとめています。

目次

第1章 重要洞察

第2章 疾患背景と概要

  • イントロダクション
  • 脊髄小脳変性症(SCA)の病型
    • 1型(SCA1)
    • 2型(SCA2)
    • 3型(SCA3)
    • 6型(SCA6)
    • 7型(SCA7)
  • 原因と危険因子
  • 歴史
  • 兆候と症状
  • 病態生理
  • 診断
  • バイオマーカー
    • 神経イメージングバイオマーカー
    • 眼球運動バイオマーカー
    • 生物学的バイオマーカー

第3章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国の脊髄小脳変性症(SCA)の総有病数

第4章 脊髄小脳変性症(SCA)の疫学:国別

  • 米国
    • 仮定と根拠
    • 総有病数
    • 総診断数
    • 総有病数:病型別
  • 欧州5カ国
    • ドイツ
      • 総有病数
      • 総診断数
      • 総有病数:病型別
    • フランス
      • 総有病数
      • 総診断数
      • 総有病数:病型別
    • イタリア
      • 総有病数
      • 総診断数
      • 総有病数:病型別
    • スペイン
      • 総有病数
      • 総診断数
      • 総有病数:病型別
    • 英国
      • 総有病数
      • 総診断数
      • 総有病数:病型別
  • 日本
    • 総有病数
    • 総診断数
    • 総有病数:病型別

第5章 治療

  • 潜在的な治療
  • 米国のガイドライン
    • 宿主組織の局所感受性
  • 欧州のガイドライン
  • 脊髄小脳変性症(SCA)の管理

第6章 アンメットニーズ

第7章 付録

  • 調査手法

第8章 DelveInsightのサービス内容

第9章 免責事項

第10章 DelveInsightについて

図表

List of Tables

  • Table 1: SCA subtypes
  • Table 2: SCA subtypes with associated clinical signs
  • Table 3: Total Population of Spinocerebellar Ataxia in the 7MM (2017-2028)
  • Table 4: Total Prevalent Population of Spinocerebellar Ataxia in the United States (2017-2028)
  • Table 5: Total Diagnosed cases of Spinocerebellar Ataxia in the United States (2017-2028)
  • Table 6: Type-Specific Prevalence of Spinocerebellar Ataxia in the United States (2017-2028)
  • Table 7: Total Prevalent Population of Spinocerebellar Ataxia in Germany (2017-2028)
  • Table 8: Total Diagnosed cases of Spinocerebellar Ataxia in Germany (2017-2028)
  • Table 9: Type-Specific Prevalence of Spinocerebellar Ataxia in Germany (2017-2028)
  • Table 10: Total Prevalent Population of Spinocerebellar Ataxia in France (2017-2028)
  • Table 11: Total Diagnosed cases of Spinocerebellar Ataxia in France (2017-2028)
  • Table 12: Type-Specific Prevalence of Spinocerebellar Ataxia in France (2017-2028)
  • Table 13: Total Prevalent Population of Spinocerebellar Ataxia in Italy (2017-2028)
  • Table 14: Total Diagnosed cases of Spinocerebellar Ataxia in Italy (2017-2028)
  • Table 15: Type-Specific Prevalence of Spinocerebellar Ataxia in Italy (2017-2028)
  • Table 16: Total Prevalent Population of Spinocerebellar Ataxia in Spain (2017-2028)
  • Table 17: Total Diagnosed cases of Spinocerebellar Ataxia in Spain (2017-2028)
  • Table 18: Type-Specific Prevalence of Spinocerebellar Ataxia in Spain (2017-2028)
  • Table 19: Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Table 20: Total Diagnosed cases of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Table 21: Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Table 22: Total Prevalent Population of Spinocerebellar Ataxia in Japan (2017-2028)
  • Table 23: Total Diagnosed cases of Spinocerebellar Ataxia in Japan (2017-2028)
  • Table 24: Type-Specific Prevalence of Spinocerebellar Ataxia in Japan (2017-2028)

List of Figures

  • Figure 1: SCA subtypes overall prevalence
  • Figure 2: Repeat expansions that cause ataxia
  • Figure 3: Harding's classification of Spinocerebellar Ataxia, detailing the classification of SCA based on symptom presentation
  • Figure 4: Common disease mechanisms underlying SCAs.
  • Figure 5: Flowchart of molecular genetic diagnosis of SCAs
  • Figure 6: Total Prevalent Patient Population of Spinocerebellar Ataxia in the 7MM (2017-2028)
  • Figure 7: Total Prevalent Population of Spinocerebellar Ataxia in the United States (2017-2028)
  • Figure 8: Total Diagnosed cases of Spinocerebellar Ataxia in the United States (2017-2028)
  • Figure 9:Type-Specific Prevalence of Spinocerebellar Ataxia in the United States (2017-2028)
  • Figure 10: Total Prevalent Population of Spinocerebellar Ataxia in Germany (2017-2028)
  • Figure 11: Total Diagnosed cases of Spinocerebellar Ataxia in Germany (2017-2028)
  • Figure 12: Type-Specific Prevalence of Spinocerebellar Ataxia in Germany (2017-2028)
  • Figure 13: Total Prevalent Population of Spinocerebellar Ataxia in France (2017-2028)
  • Figure 14: Total Diagnosed cases of Spinocerebellar Ataxia in France (2017-2028)
  • Figure 15:Type-Specific Prevalence of Spinocerebellar Ataxia in France (2017-2028)
  • Figure 16: Total Prevalent Population of Spinocerebellar Ataxia in Italy (2017-2028)
  • Figure 17: Total Diagnosed cases of Spinocerebellar Ataxia in Italy (2017-2028)
  • Figure 18: Type-Specific Prevalence of Spinocerebellar Ataxia in Italy (2017-2028)
  • Figure 19: Total Prevalent Population of Spinocerebellar Ataxia in Spain (2017-2028)
  • Figure 20: Total Diagnosed cases of Spinocerebellar Ataxia in Spain (2017-2028)
  • Figure 21:Type-Specific Prevalence of Spinocerebellar Ataxia in Spain (2017-2028)
  • Figure 22: Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Figure 23: Total Diagnosed cases of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Figure 24:Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Figure 25: Total Prevalent Population of Spinocerebellar Ataxia in Japan (2017-2028)
  • Figure 26: Total Diagnosed cases of Spinocerebellar Ataxia in Japan (2017-2028)
  • Figure 27: Type-Specific Prevalence of Spinocerebellar Ataxia in Japan (2017-2028)
  • Figure 28: Unmet Needs of Spinocerebellar ataxia
目次
Product Code: DIEI0377

DelveInsight's ‘Spinocerebellar Ataxia (SCA)- Epidemiology Forecast to 2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Spinocerebellar Ataxia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028.

Disease Understanding:

Spinocerebellar Ataxia is a genetic disorder which is progressive, degenerative, and often fatal. The clinical marker of all SCAs is a progressive loss of balance and coordination accompanied by slurred speech. The mobility and communicative skills of individuals with an SCA are restricted, which strongly impairs quality of life, and many SCAs lead to premature death.

Spinocerebellar Ataxia Epidemiology:

The Spinocerebellar Ataxia (SCA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Spinocerebellar Ataxia are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Spinocerebellar Ataxia Epidemiology Segmentation:

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Spinocerebellar Ataxia and type-specific prevalent cases) scenario of Spinocerebellar Ataxia (SCA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Spinocerebellar Ataxia (SCA) in 7 MM was found to be 42,043, in the year 2017.

Report Scope:

  • The report covers detailed overview of Spinocerebellar Ataxia explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Spinocerebellar Ataxia in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by prevalence of SCA, total diagnosed prevalence of Spinocerebellar Ataxia, incidence of Spinocerebellar Ataxia, and type-specific prevalent cases in 7MM

Key strengths:

  • 10 Year Forecast of Spinocerebellar Ataxia epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of SCA
  • Prevalent Cases according to segmentation: Prevalence, Diagnosed Cases, Type specific

Key assessments:

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Disease Background and Overview

  • 2.1. Introduction
  • 2.2. Subtypes of SCA
    • 2.2.1. SCA1
    • 2.2.2. SCA2
    • 2.2.3. SCA3
    • 2.2.4. SCA6
    • 2.2.5. SCA7
  • 2.3. Causes and risk factors
  • 2.4. History
  • 2.5. Signs and Symptoms
  • 2.6. Pathophysiology
  • 2.7. Diagnosis
  • 2.8. Biomarkers
    • 2.8.1. Neuroimaging biomarkers
    • 2.8.2. Oculomotor biomarkers
    • 2.8.3. Biological biomarkers

3. Epidemiology and Patient Population

  • 3.1. Key Findings
  • 3.2. 7MM Total Patient Population of Spinocerebellar Ataxia

4. Country Wise-Epidemiology of Spinocerebellar Ataxia

  • 4.1. United States
    • 4.1.1. Assumptions and Rationale
    • 4.1.2. Total Prevalent Population of Spinocerebellar Ataxia in the United States
    • 4.1.3. Total Diagnosed Cases of Spinocerebellar Ataxia in the United States
    • 4.1.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the United States
  • 4.2. EU5 Countries
    • 4.2.1. Assumptions and Rationale
  • 4.3. Germany
    • 4.3.1. Total Prevalent Population of Spinocerebellar Ataxia in Germany
    • 4.3.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Germany
    • 4.3.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the Germany
  • 4.4. France
    • 4.4.1. Total Prevalent Population of Spinocerebellar Ataxia in France
    • 4.4.2. Total Diagnosed Cases of Spinocerebellar Ataxia in France
    • 4.4.3. Type-Specific Prevalence of Spinocerebellar Ataxia in France
  • 4.5. Italy
    • 4.5.1. Total Prevalent Population of Spinocerebellar Ataxia in Italy
    • 4.5.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Italy
    • 4.5.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Italy
  • 4.6. Spain
    • 4.6.1. Total Prevalent Population of Spinocerebellar Ataxia in Spain
    • 4.6.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Spain
    • 4.6.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Spain
  • 4.7. United Kingdom
    • 4.7.1. Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom
    • 4.7.2. Total Diagnosed Cases of Spinocerebellar Ataxia in the United Kingdom
    • 4.7.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom
  • 4.8. Japan
    • 4.8.1. Assumptions and Rationale
    • 4.8.2. Total Prevalent Population of Spinocerebellar Ataxia in Japan
    • 4.8.3. Total Diagnosed Cases of Spinocerebellar Ataxia in Japan
    • 4.8.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the Japan

5. Treatments

  • 5.1. Potential treatments
  • 5.2. U.S. Guidelines
    • 5.2.1. Local Susceptibility of Host Tissue
  • 5.3. Europe Guidelines
  • 5.4. Management of Spinocerebellar Ataxia

6. Unmet Needs

7. Appendix

  • 7.1. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

Back to Top